LogicBio Therapeutics (LOGC) – Business Wire
-
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
-
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
-
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
-
AavantiBio Deepens AAV Manufacturing Capabilities with Key Hires to Support Strategic Growth
Back to LOGC Stock Lookup